Advice
Following a full submission.
Pioglitazone (Actos?) is not recommended for use within NHS Scotland as monotherapy for patients with type 2 diabetes mellitus.
It is one of two peroxisome proliferator-activated receptor-??agonists recently marketed in the UK for this indication. In controlling blood glucose, its mid range and maximum doses were non-inferior to standard sulphonylurea therapies. The economic case for pioglitazone has not been demonstrated.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- Pioglitazone (Actos®)
- SMC ID:
- 115/04
- Indication:
- Type 2 diabetes mellitus patients for whom metformin is inappropriate
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 August 2004